Scarica l'app Stockscreener
1,040.00
0.17%
1.73
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché LLY Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$1,038.27
Aprire:
$1039.98
Volume 24 ore:
2.70M
Relative Volume:
0.79
Capitalizzazione di mercato:
$930.82B
Reddito:
$65.18B
Utile/perdita netta:
$20.64B
Rapporto P/E:
45.31
EPS:
22.9554
Flusso di cassa netto:
$6.44B
1 W Prestazione:
-1.72%
1M Prestazione:
-3.45%
6M Prestazione:
+57.46%
1 anno Prestazione:
+19.29%
Intervallo 1D:
$1,033.69
$1,064.34
Intervallo di 1 settimana:
$1,012.00
$1,106.94
Portata 52W:
$623.78
$1,133.95
Lilly Eli Co Stock (LLY) Company Profile
Nome
Lilly Eli Co
Settore
Industria
Telefono
(317) 276-2000
Indirizzo
LILLY CORPORATE CTR, INDIANAPOLIS, IN
Compare LLY vs JNJ, ABBV, AZN, NVS
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
LLY
Lilly Eli Co
|
1,040.00 | 929.27B | 65.18B | 20.64B | 6.44B | 22.96 |
|
JNJ
Johnson Johnson
|
243.45 | 589.19B | 94.19B | 26.80B | 19.70B | 11.05 |
|
ABBV
Abbvie Inc
|
231.50 | 402.08B | 61.16B | 4.20B | 19.68B | 2.3671 |
|
AZN
Astrazeneca Plc
|
205.55 | 317.06B | 58.80B | 10.24B | 8.98B | 3.2788 |
|
NVS
Novartis Ag Adr
|
163.10 | 307.56B | 54.72B | 14.02B | 15.32B | 7.1855 |
Lilly Eli Co Stock (LLY) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-07 | Ripresa | UBS | Buy |
| 2025-12-16 | Aggiornamento | Daiwa Securities | Neutral → Buy |
| 2025-12-15 | Reiterato | BofA Securities | Buy |
| 2025-12-15 | Reiterato | Goldman | Buy |
| 2025-11-13 | Iniziato | Scotiabank | Sector Outperform |
| 2025-11-10 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2025-10-20 | Reiterato | BMO Capital Markets | Outperform |
| 2025-10-14 | Aggiornamento | Erste Group | Hold → Buy |
| 2025-09-17 | Downgrade | Berenberg | Buy → Hold |
| 2025-08-27 | Aggiornamento | HSBC Securities | Reduce → Hold |
| 2025-08-18 | Downgrade | Daiwa Securities | Outperform → Neutral |
| 2025-08-07 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2025-06-05 | Downgrade | Erste Group | Buy → Hold |
| 2025-04-28 | Downgrade | HSBC Securities | Buy → Reduce |
| 2025-04-22 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-12-10 | Ripresa | BofA Securities | Buy |
| 2024-11-15 | Iniziato | Wolfe Research | Outperform |
| 2024-10-17 | Iniziato | Bernstein | Outperform |
| 2024-09-13 | Ripresa | Citigroup | Buy |
| 2024-08-12 | Aggiornamento | Deutsche Bank | Hold → Buy |
| 2024-02-21 | Downgrade | DZ Bank | Buy → Hold |
| 2024-02-16 | Reiterato | Morgan Stanley | Overweight |
| 2023-12-21 | Downgrade | Daiwa Securities | Buy → Outperform |
| 2023-11-09 | Iniziato | Deutsche Bank | Hold |
| 2023-10-20 | Ripresa | UBS | Buy |
| 2023-08-09 | Aggiornamento | Jefferies | Hold → Buy |
| 2023-07-26 | Reiterato | Citigroup | Buy |
| 2023-07-14 | Iniziato | HSBC Securities | Buy |
| 2023-05-24 | Reiterato | BofA Securities | Buy |
| 2023-05-24 | Reiterato | UBS | Buy |
| 2023-03-13 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2023-03-06 | Iniziato | Jefferies | Hold |
| 2023-02-15 | Downgrade | Societe Generale | Hold → Sell |
| 2022-11-18 | Iniziato | Credit Suisse | Outperform |
| 2022-09-22 | Aggiornamento | UBS | Neutral → Buy |
| 2022-05-23 | Iniziato | SVB Leerink | Outperform |
| 2022-04-06 | Ripresa | Morgan Stanley | Overweight |
| 2022-03-10 | Iniziato | Daiwa Securities | Outperform |
| 2022-01-21 | Aggiornamento | DZ Bank | Hold → Buy |
| 2022-01-03 | Reiterato | Bernstein | Mkt Perform |
| 2021-12-17 | Iniziato | Goldman | Neutral |
| 2021-12-16 | Reiterato | BMO Capital Markets | Outperform |
| 2021-12-16 | Reiterato | BofA Securities | Buy |
| 2021-12-09 | Ripresa | Wells Fargo | Equal Weight |
| 2021-11-19 | Iniziato | BMO Capital Markets | Outperform |
| 2021-10-11 | Aggiornamento | Berenberg | Hold → Buy |
| 2021-09-29 | Aggiornamento | Citigroup | Neutral → Buy |
| 2021-08-05 | Aggiornamento | DZ Bank | Hold → Buy |
| 2021-07-27 | Ripresa | Truist | Buy |
| 2021-06-24 | Reiterato | Cantor Fitzgerald | Overweight |
| 2021-01-19 | Aggiornamento | Mizuho | Neutral → Buy |
| 2020-12-10 | Aggiornamento | Wolfe Research | Peer Perform → Outperform |
| 2020-11-10 | Ripresa | Bernstein | Mkt Perform |
| 2020-09-29 | Iniziato | Berenberg | Hold |
| 2020-09-03 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2020-06-16 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2020-04-21 | Downgrade | UBS | Buy → Neutral |
| 2020-04-09 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-02-06 | Iniziato | Mizuho | Neutral |
| 2019-12-18 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2019-10-17 | Ripresa | BofA/Merrill | Buy |
| 2019-05-28 | Iniziato | Goldman | Buy |
| 2019-04-24 | Aggiornamento | Edward Jones | Hold → Buy |
| 2019-04-11 | Downgrade | Guggenheim | Buy → Neutral |
| 2019-03-12 | Iniziato | JP Morgan | Overweight |
| 2019-01-23 | Iniziato | UBS | Buy |
| 2018-11-26 | Downgrade | Citigroup | Buy → Neutral |
| 2018-10-31 | Aggiornamento | Credit Suisse | Underperform → Neutral |
| 2018-10-09 | Iniziato | Guggenheim | Buy |
| 2018-10-01 | Reiterato | SunTrust | Buy |
| 2018-09-26 | Ripresa | JP Morgan | Overweight |
Mostra tutto
Lilly Eli Co Borsa (LLY) Ultime notizie
CRISPR Therapeutics Spotlights Momentum For Lead Gene Therapy As Adoption Widens - Benzinga
Eli Lilly (LLY) Prepares Orforglipron Inventory Ahead of FDA Dec - GuruFocus
Did Eli Lilly Just Make a Deal for Its Next Blockbuster Drug? - The Motley Fool
Eli Lilly (LLY) Retains Buy Rating on Strong 2026 Outlook - Insider Monkey
Eli Lilly and Company (LLY) Gets Upgraded to Buy From Hold by Freedom Capital - Finviz
Eli Lilly and Company (NYSE:LLY) Stock Price Expected to Rise, CICC Research Analyst Says - MarketBeat
Rx Rundown: Eli Lilly, Supreme Group, Regenxbio and more - Medical Marketing and Media
Eli Lilly boosts weight loss pill inventory ahead of FDA decision - Seeking Alpha
Eli Lilly and Company $LLY Shares Bought by Public Sector Pension Investment Board - MarketBeat
Eli Lilly Builds $1.5 Billion Inventory Of Experimental Weight-Loss Pill As FDA Decision Looms - Benzinga
City Council approves $6 billion Eli Lilly plant, addresses recycling issues - WAFF
Lilly Stock Upgraded to Strong Buy as Growth Momentum and RNA Therapeutics Bet Take Center Stage - AD HOC NEWS
Eli Lilly Uses GLP 1 Cash Flows To Pursue Next Wave RNA Therapies - simplywall.st
Eli Lilly builds $1.5 billion stockpile of weight-loss pill ahead of FDA decision - Reuters
ELI LILLY & Co SEC 10-K Report - TradingView
Eli Lilly Stock (LLY) Gets New ‘Buy Rating’ After Strong Earnings - TipRanks
Lilly’s $2.4B bet on off-the-shelf cell therapy is part of a wider Big Pharma shift - PharmaVoice
Eli Lilly and Company $LLY Stock Position Increased by Varma Mutual Pension Insurance Co - MarketBeat
How to Play Eli Lilly Stock Following a Robust Q4 Earnings Report - Nasdaq
Savvy Advisors Inc. Has $7.36 Million Position in Eli Lilly and Company $LLY - MarketBeat
Eli Lilly (NYSE: LLY) Stock Price Prediction and Forecast 2026-2030 (Jan 2026) - 24/7 Wall St.
Eli Lilly and Company (NYSE:LLY) Stock Rating Upgraded by Freedom Capital - MarketBeat
Eli Lilly Extends Lead in Weight-Loss Drug Market - AD HOC NEWS
Fund Update: 382,112 ELI LILLY (LLY) shares added to PARNASSUS INVESTMENTS, LLC portfolio - Quiver Quantitative
Illinois Municipal Retirement Fund Sells 1,002 Shares of Eli Lilly and Company $LLY - MarketBeat
Eli Lilly vs Novo Nordisk in the Weight Loss Drug Market: Here's What Investors Need to Know. - Yahoo Finance
Atria Investments Inc Has $30.79 Million Stake in Eli Lilly and Company $LLY - MarketBeat
Is Eli Lilly and Company (NYSE:LLY) Strengthening its Position In S&P 500 Futures - Kalkine Media
Eli Lilly Leadership Receives Stock Awards Amid Strong Growth Forecast - AD HOC NEWS
Eli Lilly and Company (LLY) to Acquire Orna Therapeutics in $2.4B Deal to Expand RNA Pipeline - Insider Monkey
7th Circ. Mulls Expiration Date Of Teva, Eli Lilly Patent Deal - Law360
Novo to Follow Lilly and Sell Obesity Shot Wegovy in Vials - Bloomberg.com
Top Analyst Reports for Eli Lilly, Marriott & Fortinet - TradingView
Robust Demand for Eli Lilly and Company (LLY)'s Obesity and Diabetes Treatments Drives Strong Investor Sentiment - Finviz
Robust Demand for Eli Lilly and Company (LLY)’s Obesity and Diabetes Treatments Drives Strong Investor Sentiment - Yahoo Finance
3 Reasons to Buy Eli Lilly Stock - Yahoo Finance
Novo Nordisk Reportedly Eyes Launching Wegovy In Vials To Compete With Rival Eli Lilly - Stocktwits
Ex-Dividend Reminder: Bio-Techne, 3M and Eli Lilly - Nasdaq
Eli Lilly and Company $LLY Shares Bought by Westbourne Investments Inc. - MarketBeat
Krilogy Financial LLC Acquires Shares of 4,276 Eli Lilly and Company $LLY - MarketBeat
Mechanics Financial Corp Has $1.98 Million Stock Holdings in Eli Lilly and Company $LLY - MarketBeat
Eli Lilly and Company $LLY Shares Sold by Rhumbline Advisers - MarketBeat
Eli Lilly and Company $LLY Stock Position Raised by Madison Asset Management LLC - MarketBeat
Stratos Wealth Partners LTD. Grows Position in Eli Lilly and Company $LLY - MarketBeat
Eli Lilly and Company $LLY Shares Acquired by Jensen Investment Management Inc. - MarketBeat
The Top 5 Analyst Questions From Eli Lilly's Q4 Earnings Call - Finviz
CICC Adjusts Price Target on Eli Lilly and Co. to $1,107 From $1,060, Maintains Neutral Rating - marketscreener.com
Cibc World Market Inc. Buys 49,634 Shares of Eli Lilly and Company $LLY - MarketBeat
61,694 Shares in Eli Lilly and Company $LLY Acquired by Caprock Group LLC - MarketBeat
ING Groep NV Buys 132,234 Shares of Eli Lilly and Company $LLY - MarketBeat
Eli Lilly buys Orna Therapeutics for US$2.4bn - Health Tech World
Lilly Eli Co Azioni (LLY) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.45%
1.76%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):